Patent ID: 6103238
Filing Date: 2000-08-15
Classification: A61K,A61P,C07K,C12N

Abstract:
A composition comprising a mutant recombinant human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein which is mutated in its primary amino acid sequence with respect to a wild type HIV-1 envelope glycoprotein, said mutant glycoprotein including two or more N-linked carbohydrate consensus amino acid sequence mutations so as to effect partial deglycosylation, said mutation being positioned between the C terminus of gp120 and the Cys at the N-terminal side of the gp120 cysteine loop containing the third hypervariable sequence (V3), said Cys being approximately at amino acid position 296, said mutant glycoprotein being sufficiently deglycosylated such that the total molecular mass of the mutant gp120 component is less than 75% of the corresponding fully glycosylated wild type gp120 component, said mutant glycoprotein being effective, when present as a component of a complete HIV virion, to enable viral infectivity.